<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20160307026950N55</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-12-14</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of sedative and analgesic effects of two combinations of dexmethomidine-ketamine (Ketodex) and propofol-fentanyl (Fenofol)</public_title>
      <acronym></acronym>
      <scientific_title>A comparative study of the sedative and analgesic effects of two combinations of dexmethomidine-ketamine (Ketodex) and propofol-fentanyl (Fenofel) in patients undergoing endoscopic retrograde cholangiopancreatography.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/74176</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization is done in a simple way. The samples are
randomly placed in three intervention groups 1, 2
by means of random allocation software. Sampling
continues until the samples in all two groups reach the
set limit, Blinding description: This study is a triple blind clinical trial, before obtaining the consent to participate in the study from the patients, in addition to explaining to them that they are randomly participating in two drug groups and they will get information about the type of drugs, but in what They will not be informed if they are placed in a group, an anesthesiologist, as the person responsible for collecting data and evaluating the outcome, is not aware of the groups, nor is the statistician, who plays the role of an analyst, aware of the groups, and after receiving the results by the presenter Decoding takes place, so we can do the study in a triple blind way.</study_design>
      <phase>3</phase>
      <hc_freetext>Analgesia and sedation in patients undergoing endoscopic retrograde cholangiopancreatography.</hc_freetext>
      <i_freetext>Intervention 1: The first intervention group: received 1 μg/kg of fentanyl and 1 mg/kg of propofol in 30 seconds and then propofol injection at 2 to 4 mg/kg per hour. The second intervention group: 0.5 μg/kg of dexmedetomidine and 1 mg/kg of ketamine in 2 divided boluses of each drug, alternately in 30 seconds, and 0.5 μg/kg per hour of dexmedetomidine and ketamine with 1 to 2 will receive mg/kg per hour. Intervention 2: Intervention group: 2nd: Half microgram/kg of dexmedetomidine and 1 mg/kg of ketamine were given as a loading dose over 2 to 5 minutes as infusion, and 0.5 microgram/kg per hour of dexmedetomidine and ketamine with 1 to 2 mg/ kg per hour .</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sorour sadat Asayesh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hakim Nizami St</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174618731</zip>
        <telephone>+98 31 3627 9414</telephone>
        <email>sorourasayesh@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Azim Honarmand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Anesthesiology, AL-Zahra Hospital</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174675731</zip>
        <telephone>+98 31366855552532</telephone>
        <email>honarmand@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age over 18 years
Consent to enter the study
Patients who are candidates for endoscopic retrograde cholangiopancreatography
Patients with American Society of Anesthesiologists (ASA) I,II</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with high blood pressure, coronary heart disease and central nervous system disorders
Patients with known allergies to study drugs
pregnancy
Airway's disease</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The first intervention group: received 1 μg/kg of fentanyl and 1 mg/kg of propofol in 30 seconds and then propofol injection at 2 to 4 mg/kg per hour. The second intervention group: 0.5 μg/kg of dexmedetomidine and 1 mg/kg of ketamine in 2 divided boluses of each drug, alternately in 30 seconds, and 0.5 μg/kg per hour of dexmedetomidine and ketamine with 1 to 2 will receive mg/kg per hour.</i_keyword>
      <i_keyword>Intervention group: 2nd: Half microgram/kg of dexmedetomidine and 1 mg/kg of ketamine were given as a loading dose over 2 to 5 minutes as infusion, and 0.5 microgram/kg per hour of dexmedetomidine and ketamine with 1 to 2 mg/ kg per hour .</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Sedation rate of patients. Timepoint: The base time (before the start of the intervention) and then every 15 minutes in the operating room and in the first hour of recovery every 15 minutes to 45 minutes and then in the 2nd and 4th hours after ERCP were recorded. Method of measurement: The level of patients sedation will be evaluated using the Modified Aldrete score,whose validity and reliability have been confirmed by a recent stud.</prim_outcome>
      <prim_outcome>Analgesia of patients. Timepoint: The base time (before the start of the intervention) and then every 15 minutes in the operating room and in the first hour of recovery every 15 minutes to 45 minutes and then in the 2nd and 4th hours after ERCP were recorded. Method of measurement: Painlessness of patients will be evaluated using the Visual Analogue Scale (VAS) whose validity and reliability have been confirmed by a recent study.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Systolic blood pressure. Timepoint: The base time (before the start of the intervention) and then every 15 minutes in the operating room and in the first hour of recovery every 15 minutes to 45 minutes and then in the 2nd and 4th hours after ERCP were recorded. Method of measurement: Barometer.</sec_outcome>
      <sec_outcome>Diastolic blood pressure. Timepoint: The base time (before the start of the intervention) and then every 15 minutes in the operating room and in the first hour of recovery every 15 minutes to 45 minutes and then in the 2nd and 4th hours after ERCP were recorded. Method of measurement: Barometer.</sec_outcome>
      <sec_outcome>Pulse rate. Timepoint: The base time (before the start of the intervention) and then every 15 minutes in the operating room and in the first hour of recovery every 15 minutes to 45 minutes and then in the 2nd and 4th hours after ERCP were recorded. Method of measurement: ECG.</sec_outcome>
      <sec_outcome>Respiratory rate. Timepoint: The base time (before the start of the intervention) and then every 15 minutes in the operating room and in the first hour of recovery every 15 minutes to 45 minutes and then in the 2nd and 4th hours after ERCP were recorded. Method of measurement: Breaths per minute stopwatch.</sec_outcome>
      <sec_outcome>Oxygen saturation. Timepoint: The base time (before the start of the intervention) and then every 15 minutes in the operating room and in the first hour of recovery every 15 minutes to 45 minutes and then in the 2nd and 4th hours after ERCP were recorded. Method of measurement: Pulse oximeter.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-08-08</approval_date>
        <contact_name>Ethics committee of Isfahan University of Medical Sciences</contact_name>
        <contact_address>Isfahan University of Medical Sciences, Hezar Jarib street, Azadi square, Isfahan Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
